Eunpi Cho, M.D., Hematologic Oncologist; Palo Alto Medical Foundation

California Pacific CURRENTS: The online journal of CPMC Research Institute

Leading research advances in the treatment of breast and prostate cancer

Research Overview

  • Dr. Eunpi Cho is board certified in internal medicine, hematology, and oncology. She has a special interest in treating patients with breast and prostate cancer.
  • In addition to patient care, Dr. Cho leads treatment advances through her research into novel therapies and optimal management of patients with newly diagnosed and advanced cancers.
  • Dr. Cho is a Principal Investigator for National Cancer Institute Cancer and Leukemia Group B (CALGB) and Alliance for Clinical Trials in Oncology group clinical trials. She has authored numerous publications, book chapters and abstracts on emerging treatment options for solid cancers and hematologic malignancies.
  • She is the Sutter site Principal Investigator for a Patient-Centered Outcomes Research Institute (PCORI) study to design a tool for patient-reported outcome measures assessing symptom and physical function as part of quality assessment for cancer care.  The multi-institution study involves collaboration with Palo Alto Medical Foundation Research Institute (PAMFRI).


Read more about research among the Sutter Cancer Research Consortium.

Find additional information on oncology research and clinical trials at Palo Alto Medical Foundation.


Dr. Cho received her M.D. from Johns Hopkins University School of Medicine. She completed residency training in internal medicine at Johns Hopkins Hospital, and a fellowship in hematology-oncology at the Fred Hutchinson Cancer Research Center in Seattle, Washington.

Publication Search


Mostaghel EA, Cho E, Zhang A, Alyamani M, Kaipainen A, Green S, Marck BT, Sharifi N, Wright JL, Gulati R, True LD, Loda M, Matsumoto AM, Tamae D, Penning TN, Balk SP, Kantoff PW, Nelson PS, Taplin ME, Montgomery RB, Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. Clin Cancer Res

Norsworthy KJ, Cho E, Arora J, Kowalski J, Tsai HL, Warlick E, Showel M, Pratz KW, Sutherland LA, Gore SD, Ferguson A, Sakoian S, Greer J, Espinoza-Delgado I, Jones RJ, Matsui WH, Smith BD, Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies. Leuk Res

Cho E, Mostaghel EA, Russell KJ, Liao JJ, Montgomery B, In Reply to Bhattacharyya et al. Int J Radiat Oncol Biol Phys

Cho E, Schwemm AK, Rubinstein LM, Stevenson PA, Gooley TA, Ellis GK, Specht JM, Livingston RB, Linden HM, Gadi VK, Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is New. Clin Breast Cancer

Eunpi  Cho, M.D., Hematologic Oncologist; Palo Alto Medical Foundation
Primary Research Interests
  • Patient-centered outcomes
  • Treatment of solid tumors